Cargando…

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have a high incidence of renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) expressions. The purpose of this study was to evaluate the anticancer activity of dapagliflozin as an SGLT2 inhibitor on RCC cell lines in v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuang, Haoyu, Liao, Liya, Chen, Hongtao, Kang, Qian, Shu, Xiaochun, Wang, Yanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Animal Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549715/ https://www.ncbi.nlm.nih.gov/pubmed/28763435 http://dx.doi.org/10.12659/MSM.902530

Ejemplares similares

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
por: Shin, Seok Joon, et al.
Publicado: (2016)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review
por: Gul, Wajiha, et al.
Publicado: (2021)

Effect of Nitric Oxide Pathway Regulation on Water/Sodium Balance and Renal Function in a Rodent Model of Acute Liver and Renal Failure
por: Saracyn, Marek, et al.
Publicado: (2014)

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
por: Wilcox, Christopher S., et al.
Publicado: (2018)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
por: Wang, Dong, et al.
Publicado: (2018)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
por: Tahrani, Abd A., et al.
Publicado: (2011)

Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin
por: Furuya, Futoshi, et al.
Publicado: (2022)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023)

Safety and effectiveness of the sodium‐glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus
por: Hadd, Michael J., et al.
Publicado: (2023)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
por: Chiba, Yumiko, et al.
Publicado: (2016)

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
por: Yu, Yong-Wei, et al.
Publicado: (2022)

Mechanism Underlying Acupuncture-Ameliorated Depressive Behaviors by Enhancing Glial Glutamate Transporter in Chronic Unpredictable Mild Stress (CUMS) Rats
por: Luo, Ding, et al.
Publicado: (2017)

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
por: Reilly, Timothy P., et al.
Publicado: (2014)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Effect of Parecoxib Sodium on Myocardial Ischemia-Reperfusion Injury Rats
por: Wu, Fangyong, et al.
Publicado: (2021)

Different Effect of Handle Region Peptide on β-Cell Function in Different Sexes of Rats Neonatally Treated with Sodium L-Glutamate
por: Wu, Yi-xi, et al.
Publicado: (2015)

Therapeutic Effects of Sleeve Gastrectomy and Ileal Transposition on Type 2 Diabetes in a Non-Obese Rat Model by Regulating Blood Glucose and Reducing Ghrelin Levels
por: Wang, Hui, et al.
Publicado: (2019)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes?
por: Hinton, William, et al.
Publicado: (2020)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
por: Choi, Min-Koo, et al.
Publicado: (2020)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Effect of Cinnamaldehyde on Glucose Metabolism and Vessel Function
por: Guo, Xuan, et al.
Publicado: (2017)

Effect of Sodium Valproate on Cognitive Function and Hippocampus of Rats After Convulsive Status Epilepticus
por: Wu, Peng, et al.
Publicado: (2016)

Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury
por: Xu, Xingkai, et al.
Publicado: (2020)

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
por: Terami, Naoto, et al.
Publicado: (2014)

Effect of Three Statins on Glucose Uptake of Cardiomyocytes and its Mechanism
por: Jiang, Zhenhuan, et al.
Publicado: (2016)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Differential effects of selective and non-selective nitric oxide synthase inhibitors on the blood perfusion of ischemia-reperfused myocardium in dogs
por: Luo, Yi, et al.
Publicado: (2013)

Tetramethylpyrazine Protects Neurons from Oxygen-Glucose Deprivation-Induced Death
por: Shao, Zhengkai, et al.
Publicado: (2017)

Sodium Caseinate (CasNa) Induces Mobilization of Hematopoietic Stem Cells in a BALB/c Mouse Model
por: Santiago-Osorio, Edelmiro, et al.
Publicado: (2015)

Sodium Tanshinone IIA Sulfonate Improves Hemodynamic Parameters, Cytokine Release, and Multi-Organ Damage in Endotoxemia Rabbits
por: Ma, Shaolei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_86hc6f1uf8t8evv2j4dlogrp6g